Go To Global Site
Welcome to UCB in the United States

Newsroom

Find U.S. news and updates from UCB, a global biopharmaceutical company focused on creating value for people living with severe diseases, such as epilepsy, Parkinson’s disease, psoriasis, osteoporosis, myasthenia gravis,  rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, and more. 

Spotlight Story

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

 

 

UCB U.S. News

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Read More

UCB to acquire Zogenix

Read More

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

Read More

Twitter Feed

For More Information